TG TherapeuticsTGTX
TGTX
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
53% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 55
23% more capital invested
Capital invested by funds: $2.36B [Q3] → $2.91B (+$552M) [Q4]
22% more call options, than puts
Call options by funds: $137M | Put options by funds: $113M
7% more funds holding
Funds holding: 303 [Q3] → 325 (+22) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 96
3.01% less ownership
Funds ownership: 65.2% [Q3] → 62.19% (-3.01%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$55
49%
upside
Avg. target
$55
49%
upside
High target
$55
49%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Edward White 19% 1-year accuracy 29 / 149 met price target | 49%upside $55 | Buy Reiterated | 4 Mar 2025 |
Financial journalist opinion
Based on 4 articles about TGTX published over the past 30 days
Positive
Zacks Investment Research
1 week ago
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why
Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.
Neutral
GlobeNewsWire
1 week ago
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below.
Neutral
GlobeNewsWire
1 week ago
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below.
Neutral
GlobeNewsWire
2 weeks ago
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and the other detailing the experience of seven individuals with MS who switched to BRIUMVI® (ublituximab-xiiy) from a different anti-CD20 monoclonal antibody therapy due to efficacy or tolerability concerns. Details of the publications are provided below.
Positive
Investors Business Daily
1 month ago
These Insurance Stocks And Biotech Leader Hit New Highs As Stock Market Crumbles
Insurance stock Root soared to a new high on Friday. The IBD 50 holding has an ideal Composite and Relative Strength Rating.
Positive
Benzinga
1 month ago
Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher
Trading is subdued with TG Therapeutics, Inc. TGTX on Friday. But the shares remain in an uptrend and there is a good chance the trend will continue.
Positive
Zacks Investment Research
1 month ago
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?
TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Positive
Seeking Alpha
1 month ago
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel
Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer and autoimmune disorders. TG Therapeutics' BRIUMVI achieved significant sales growth in 2024, supporting positive cash flow and funding for future developments, including azer-cel for autoimmune disorders. DTIL is rated a speculative "Buy" due to its undervaluation, promising pipeline, and strategic partnerships, while TGTX is rated "Hold" due to its full valuation.
Positive
Seeking Alpha
1 month ago
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends. Upcoming pivotal trials and potential label updates for Briumvi, including subcutaneous administration, could enhance patient convenience and treatment efficacy.
Positive
Seeking Alpha
1 month ago
TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter
TGTX's Briumvi, despite initial struggles, has shown strong performance by consistently beating earnings estimates, even with competition from Roche's Zunovo. Briumvi's competitive advantages include a shorter infusion time, lower malignancy risks, and a more favorable price compared to Ocrevus. TGTX's financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring an indefinite cash runway.
Charts implemented using Lightweight Charts™